Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients

Stefan Hohaus, Pier Luigi Zinzani, Umberto Vitolo, Simonetta Viviani, Paolo Corradini, Giovanna Motta, Monica Tani, Nicola Cascavilla, Francesco Merli, Lisa Argnani, Alessandro Broccoli

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

16 Citazioni (Scopus)

Abstract

The optimal treatment of patients with heavily pretreated Hodgkin's lymphoma is controversial. Brentuximab vedotin is an active single agent in this context. Also, bendamustine can be regarded as a safe and effective alternative for patients with relapse after autologous transplantation and as an interesting cytoreductive strategy before allogeneic transplantation.
Lingua originaleEnglish
pagine (da-a)404-408
Numero di pagine5
RivistaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume15
DOI
Stato di pubblicazionePubblicato - 2015

Keywords

  • Bendamustine
  • Brentuximab vedotin
  • Hodgkin's lymphoma
  • Refractory
  • Relapsed

Fingerprint Entra nei temi di ricerca di 'Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients'. Insieme formano una fingerprint unica.

Cita questo